Verified Nov 2026
Electronics & Software
·
San Diego, California
·
Since 2012
Biolinq is a privately held healthcare technology company headquartered in San Diego, California, founded in 2012 and operating with an estimated 100-200 employees. It develops wearable electrochemical biosensors that monitor glucose and other small-molecule analytes through a skin-applied patch. Its Shine microsensor is an intradermal glucose sensor that does not require a hypodermic needle for insertion, and the company reported FDA De Novo classification for it in 2025. The company serves the medical and digital health sectors.
Biolinq at a glance
Revenue
$10-50M
Est. band
Employees
100-200
Founded
2012
Headquarters
San Diego, California
Industries
Automotive
Electric Vehicles
Electronics
Medical
Plumbing & Hardware
Industrial Equipment
Overview
Biolinq is a privately held healthcare technology company headquartered in San Diego, California, founded in 2012 and operating with an estimated 100-200 employees. It develops wearable electrochemical biosensors that monitor glucose and other small-molecule analytes through a skin-applied patch. Its Shine microsensor is an intradermal glucose sensor that does not require a hypodermic needle for insertion, and the company reported FDA De Novo classification for it in 2025. The company serves the medical and digital health sectors.
At a glance
Attribute | Detail |
|---|---|
Founded | 2012 |
Headquarters | San Diego, California |
Employees | 100-200 |
Revenue | $10-50M (estimated) |
Primary capability | Electronics & Software |
What Biolinq makes
The company's products include skin-applied electrochemical sensors and wearable patches for continuous monitoring of glucose, ketones, and lactate.
Products and capabilities described on the company's own site include Sensor, LED (source: biolinq.com).
Latest developments
2026-09-26 — Biolinq's Shine Clears FDA for OTC Sale (regulatorynews.com)
2026-02-02 — Medtech CEO foresees smart patches becoming next wearables boom - Medical Device Network (medicaldevice-network.com)
2025-10-16 — Amalgam Rx Partners with Biolinq -- Lighting Pathways to Better Health | Amalgam Rx (amalgamrx.com)
2025-10-06 — Portfolio company Biolinq Incorporated granted De Novo Classification by U.S. FDA for its lead product | AXA IM Alts (axa-im.com)
2025-09-26 — Biolinq gets FDA de novo nod for intradermal glucose sensor | MedTech Dive (medtechdive.com)
2025-09-25 — Biolinq | News (biolinq.com)
Company details
Biolinq is privately held and reports an estimated annual revenue band of $10-50 million, and it has announced a partnership with Amalgam Rx in October 2025. Biolinq was founded in 2012, has an estimated 100-200 employees, and is headquartered in San Diego, California.
Frequently asked questions
What does Biolinq make?
Biolinq is a privately held healthcare technology company headquartered in San Diego, California, founded in 2012 and operating with an estimated 100-200 employees. It develops wearable electrochemical biosensors that monitor glucose and other small-molecule analytes through a skin-applied patch. Its Shine microsensor is an intradermal glucose sensor that does not require a hypodermic needle for insertion, and the company reported FDA De Novo classification for it in 2025. The company serves the medical and digital health sectors.
Where is Biolinq headquartered?
Biolinq is headquartered in San Diego, California (10260 Sorrento Valley Road, San Diego, California, 92121).
When was Biolinq founded?
Biolinq was founded in 2012.
How big is Biolinq?
Biolinq has an estimated 100-200 employees, with revenue in the $10-50M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.